Clinical Trial Update: A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet [Phase 2]

View source ↗

Summary

A Phase 2 dose-response study of ALK's Tree Allergy Immunotherapy Tablet for birch pollen allergy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Birch Pollen Allergy

Drugs mentioned

• ALK Tree Allergy Immunotherapy Tablet (birch pollen extract tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Birch Pollen Allergy | Phase 2 | Status: COMPLETED